Metformin Drug-Drug Interactions: A Complete Clinical Profile

How Metformin Works and Why Its Interactions Are Unique

Metformin reduces hepatic glucose output primarily by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I in liver cells. Unlike sulfonylureas or insulin, it does not cause hypoglycemia when used alone. This distinction matters for understanding its interaction profile.

No CYP450 Metabolism

Most oral medications pass through cytochrome P450 enzymes in the liver. Metformin skips this step entirely. It circulates unbound in plasma, enters hepatocytes through the organic cation transporter 1 (OCT1), and exits the body unchanged through the kidneys via OCT2-mediated secretion into renal tubules [1]. The FDA label explicitly states that metformin is "not bound to plasma proteins" and is "excreted unchanged in the urine" [2].

Transporter-Based Pharmacokinetics

Because metformin depends on cation transporters rather than enzymes, its interactions revolve around transporter competition and renal function changes. OCT1 governs how much drug reaches the liver (its site of action). OCT2 and the multidrug and toxin extrusion proteins MATE1/MATE2-K govern how quickly the kidneys clear it [3]. Any drug that inhibits these transporters can raise metformin plasma concentrations, sometimes dramatically.

This pharmacokinetic profile explains why metformin has a short list of classical "drug-drug interactions" but a long list of clinically meaningful ones that operate through renal hemodynamics and transporter interference.

OCT/MATE Transporter Interactions: The Primary Mechanism

The largest category of metformin interactions involves competition at organic cation transporters. These interactions raise metformin exposure, sometimes requiring dose adjustment.

Dolutegravir (Tivicay)

Dolutegravir inhibits OCT2 and MATE1. In a pharmacokinetic study of healthy volunteers, co-administration increased metformin AUC by 145% and C-max by 111% [4]. The FDA recommends limiting metformin to 1,000 mg daily when initiating dolutegravir, with dose adjustments guided by glycemic response [2]. This is the single largest magnitude interaction on the current metformin label.

Cimetidine

Cimetidine, an H2-receptor antagonist, inhibits OCT2 and MATE1. A classic pharmacokinetic study demonstrated a 50% increase in metformin AUC and a 81% increase in C-max during co-administration [5]. Ranitidine and famotidine show weaker OCT2 inhibition and are preferred alternatives when an H2 blocker is needed alongside metformin.

Ranolazine

Ranolazine, prescribed for chronic angina, inhibits OCT2 and raises metformin exposure by approximately 40% based on population pharmacokinetic modeling [2]. Patients on both drugs need closer glucose monitoring and may require metformin dose reduction.

Vandetanib and Other Tyrosine Kinase Inhibitors

Vandetanib inhibits OCT2 and MATE1 in vitro at clinically relevant concentrations. The FDA label for vandetanib warns of increased metformin exposure [6]. Other tyrosine kinase inhibitors (crizotinib, imatinib) show variable OCT2 inhibition, but prospective clinical data remain limited. Oncology patients starting these agents while on metformin should have renal function and blood glucose checked within 1 to 2 weeks.

Quick Reference: OCT/MATE Inhibitors and Expected Metformin AUC Changes

| Interacting Drug | Transporter Inhibited | Approximate AUC Increase | Clinical Action | |---|---|---|---| | Dolutegravir | OCT2, MATE1 | +145% | Cap metformin at 1,000 mg/day | | Cimetidine | OCT2, MATE1 | +50% | Switch to famotidine or ranitidine | | Ranolazine | OCT2 | ~40% | Monitor glucose, consider dose reduction | | Vandetanib | OCT2, MATE1 | Not fully quantified | Monitor renal function and glucose | | Trimethoprim | OCT2, MATE1 | +30-40% | Monitor during short courses |

Iodinated Contrast Media and Metformin: Lactic Acidosis Risk

The most feared metformin interaction is not with another drug but with iodinated contrast agents used in CT scans, angiography, and other imaging procedures.

The Mechanism

Iodinated contrast can cause acute kidney injury (AKI), particularly in patients with pre-existing renal impairment, diabetes, heart failure, or dehydration [7]. If renal clearance drops suddenly while metformin continues circulating, the drug accumulates. Metformin-associated lactic acidosis (MALA) carries a mortality rate of approximately 30 to 50% in case series, though incidence is rare at an estimated 3 to 10 cases per 100,000 patient-years [8].

Current ACR Guidelines

The American College of Radiology (ACR) 2024 Manual on Contrast Media stratifies risk by eGFR [7]:

• eGFR ≥ 30 mL/min/1.73 m² with no AKI risk factors: Metformin may continue. No special precautions beyond standard hydration.
• eGFR <30 mL/min/1.73 m² or AKI present: Hold metformin at the time of contrast administration. Do not restart until renal function is reassessed at 48 hours and confirmed stable.
• Emergency imaging: Do not delay the procedure to hold metformin. Reassess renal function post-procedure.

Practical Protocol

The previous blanket rule of "stop metformin 48 hours before any contrast study" is outdated. Dr. Matthew Davenport, chair of the ACR Committee on Drugs and Contrast Media, has stated: "For patients with normal renal function, there is no evidence that metformin needs to be held for routine contrast-enhanced CT" [7]. Patients with eGFR between 30 and 44 mL/min/1.73 m² represent a gray zone where individual risk assessment is appropriate.

Alcohol and Metformin

Alcohol deserves specific attention because it interacts with metformin through two separate pathways.

Lactate Accumulation

Ethanol metabolism in the liver shifts the NAD+/NADH ratio toward NADH, which impairs hepatic lactate clearance. Metformin independently increases lactate production by inhibiting mitochondrial complex I. The combination creates additive risk for lactic acidosis, though the absolute risk remains low in patients with normal hepatic and renal function [8].

Hypoglycemia With Fasting

Heavy alcohol intake suppresses gluconeogenesis. When combined with metformin (which also reduces hepatic glucose output), prolonged fasting plus alcohol can produce symptomatic hypoglycemia. This risk is most relevant in patients who skip meals while drinking. The FDA label warns against "excessive alcohol intake, acute or chronic" during metformin therapy [2].

Moderate alcohol consumption (1 drink per day for women, up to 2 for men) does not require metformin discontinuation, but patients should be counseled to eat when drinking and to avoid binge patterns.

Drugs That Impair Renal Function

Because metformin clearance tracks directly with GFR, any drug that reduces renal perfusion or causes nephrotoxicity effectively raises metformin levels.

NSAIDs

Ibuprofen, naproxen, and other NSAIDs reduce renal blood flow through prostaglandin inhibition. Chronic NSAID use in a patient on metformin can silently reduce eGFR, concentrating metformin without an obvious trigger. The ADA Standards of Care recommend checking renal function at least annually in metformin-treated patients, and more frequently if NSAIDs are used regularly [9].

ACE Inhibitors and ARBs

ACE inhibitors (lisinopril, enalapril) and ARBs (losartan, valsartan) are commonly co-prescribed with metformin in patients with type 2 diabetes and hypertension. These agents reduce efferent arteriolar pressure in the glomerulus, which can lower eGFR by 10 to 15% at initiation. This is generally hemodynamic and reversible, but in patients with eGFR near the 30 mL/min threshold, the combination warrants renal monitoring within 1 to 2 weeks of starting or up-titrating the RAAS inhibitor [10].

Aminoglycosides and Other Nephrotoxins

Gentamicin, tobramycin, amphotericin B, and cisplatin can cause acute tubular necrosis. In hospitalized patients receiving these agents, metformin should be held proactively when eGFR is trending downward.

Carbonic Anhydrase Inhibitors: Topiramate and Zonisamide

Topiramate and zonisamide inhibit carbonic anhydrase, producing a non-anion-gap metabolic acidosis by increasing renal bicarbonate wasting. Metformin, through lactate production, creates a separate acidotic stress. The combination can produce a mixed metabolic acidosis that is difficult to interpret clinically [11].

Clinical Data

A pharmacokinetic study of topiramate 100 mg twice daily with metformin 500 mg twice daily showed topiramate increased metformin AUC by 25% and C-max by 18%, while metformin decreased topiramate clearance by 20% [11]. The bidirectional nature of this interaction is unusual. The FDA label for topiramate warns that the combination "increases the risk of lactic acidosis" [2].

Monitoring Strategy

Patients on both drugs should have a basic metabolic panel checked at baseline, 1 month, and every 3 to 6 months. A serum bicarbonate below 18 mEq/L should prompt consideration of discontinuing one agent.

Drugs That Cause Hyperglycemia and Mask Metformin Efficacy

Some interactions are pharmacodynamic rather than pharmacokinetic. These agents do not change metformin blood levels but oppose its glucose-lowering effect.

Corticosteroids

Prednisone, dexamethasone, and other systemic glucocorticoids increase hepatic gluconeogenesis and reduce peripheral insulin sensitivity. A patient well-controlled on metformin 2,000 mg daily may develop fasting glucose values above 200 mg/dL within days of starting prednisone 40 mg [12]. Short courses (<7 days) may require temporary addition of a second agent or sliding-scale insulin. Prolonged courses often require formal regimen restructuring.

Atypical Antipsychotics

Olanzapine and clozapine cause weight gain and insulin resistance through mechanisms that are partially independent of weight. UKPDS 34 (N=753) demonstrated that metformin reduced diabetes-related mortality by 42% in overweight patients with type 2 diabetes [1]. Patients started on atypical antipsychotics after achieving glycemic control on metformin may lose that benefit. The ADA and American Psychiatric Association jointly recommend metabolic monitoring at baseline, 12 weeks, and annually after initiating an atypical antipsychotic [13].

Thiazide Diuretics

Hydrochlorothiazide at doses above 25 mg/day can raise fasting glucose by 5 to 10 mg/dL through potassium-mediated impairment of insulin secretion [14]. The effect is modest but measurable, and it may be mistaken for metformin failure.

Less Common but Clinically Relevant Interactions

Phenytoin and Phenobarbital

Phenytoin impairs insulin release from beta cells and can worsen glycemic control in diabetic patients [15]. The interaction with metformin is pharmacodynamic, not pharmacokinetic. Seizure patients on both agents need glucose monitoring at antiepileptic drug initiation and dose changes.

Isoniazid

Isoniazid can cause hyperglycemia through direct pancreatic beta-cell toxicity. Tuberculosis treatment in patients with type 2 diabetes on metformin should include monthly fasting glucose checks for the first 3 months.

Trimethoprim

Trimethoprim inhibits OCT2 and MATE1, raising metformin AUC by 30 to 40% during standard 7 to 14 day treatment courses [5]. For short courses treating uncomplicated urinary tract infections, this is rarely problematic. Extended trimethoprim-sulfamethoxazole use (as in Pneumocystis prophylaxis) warrants glucose monitoring and possible metformin dose reduction.

Genetic Variation in OCT Transporters

Not all patients respond identically to transporter-mediated interactions. Single-nucleotide polymorphisms in SLC22A1 (encoding OCT1) and SLC22A2 (encoding OCT2) alter metformin pharmacokinetics.

OCT1 Reduced-Function Variants

Approximately 9% of European-descent populations carry two reduced-function OCT1 alleles. These patients have lower hepatic metformin uptake, reduced glucose-lowering efficacy, and higher plasma concentrations [3]. When an OCT2 inhibitor like dolutegravir is added in a patient who already has reduced OCT1 function, the combined effect on metformin exposure may exceed what population-average data predict.

OCT2 Variants

The OCT2-808G>T (rs316019) polymorphism reduces renal metformin clearance by approximately 15 to 20% [3]. Carriers may be more sensitive to the effects of co-administered OCT2 inhibitors. Pharmacogenomic testing for OCT variants is not yet standard practice, but CPIC guidelines acknowledge the gene-drug relationship.

Monitoring Framework for Patients on Metformin Polypharmacy

Practical risk management for metformin interactions requires a systematic approach.

Baseline

• Serum creatinine and eGFR
• Basic metabolic panel (particularly bicarbonate)
• Hepatic function panel
• HbA1c

At New Drug Initiation

When starting any OCT2 inhibitor, nephrotoxin, carbonic anhydrase inhibitor, or systemic corticosteroid, recheck serum creatinine and glucose within 1 to 2 weeks. For dolutegravir specifically, limit metformin to 1,000 mg/day and titrate based on glycemic response over 4 to 8 weeks.

Ongoing

Renal function monitoring every 3 to 6 months for stable patients. Every 1 to 3 months for patients on combinations that stress renal clearance or acid-base balance. Hold metformin when eGFR drops below 30 mL/min/1.73 m² from any cause [2].

Metformin has a 60-year track record of cardiovascular benefit in type 2 diabetes, as UKPDS 34 demonstrated with a 36% reduction in all-cause mortality in the intensive metformin group versus conventional therapy (P=0.011) [1]. Managing its interactions well protects that benefit.